Jun 16, 2022 · 21m · top-founders
How he Raised $20m+ to turn his College Thesis on Dental Data into a SaaS Company
gold bands on the timeline = statements, start to end. Hover to read, click to jump. CC turns on captions
In this interview with Nathan Latka, VideaHealth founder and CEO Florian Hill discusses transforming his MIT dental AI research into a venture-backed SaaS enterprise. He details securing FDA clearance, raising $26 million in venture capital, and scaling recurring revenue across thousands of dental practices nationwide.
How this conversation actually went
Every chapter scored 0–10 on four independent dynamics. Hover any point for the reasoning behind the score. Nathan holds 39.6% of the talking time here. How this is scored →
speaking balance: gold is Nathan, purple is the guest (3 minute bins)
Florian firmly counters Nathan's claim that DSO software exists to overcharge patients, demonstrating with clinical data that young dentists routinely miss early decay.
Hardest push from Nathan ▶ 7:20 Nathan refuses conflation of contracted vs live practicesNathan directly halts Florian's marketing narrative of 3,000 practices to clarify whether they are actively deployed or merely contracted.
Biggest teaching moment ▶ 16:12 Florian explains Software as a Medical Device (SaMD)When Nathan assumes FDA approval requires physical hardware, Florian clarifies the specialized regulatory classification governing pure AI diagnostic algorithms.
Nathan holds their own ▶ 15:07 Nathan deduces revenue from pricing and practice countsNathan traps Florian's evasive revenue answer by multiplying his minimum practice count by base pricing to establish a hard MRR baseline.
the scores for every segment, with the reasoning behind each
| Chapter | Topic | Nathan as informed peer | Guest teaching | Guest disagreement | Nathan pushing back | Why |
|---|---|---|---|---|---|---|
| Florian Hill's Academic Background and Venture Inception | 4 | 5 | 3 | 5 | Nathan challenges the fundamental incentive structure of selling diagnostic software to DSOs, arguing it encourages predatory upselling. Florian pushes back on the premise by explaining that inexperienced dentists actually underdiagnose early cavities, leading to worse downstream dental outcomes. | |
| Addressing Overtreatment and Securing FDA Clearance | 6 | 3 | 2 | 7 | When Florian suggests Vidya is installed across 3,000 offices, Nathan rigorously presses him on contracted versus live deployments. Nathan forces Florian to admit that actual live deployments are currently in the low hundreds rather than the headline 3,000 figure. | |
| Origins at MIT and Navigating Dental AI Regulations | 2 | 4 | 1 | 1 | Florian describes spinning the company out of MIT and Harvard research and having to educate the FDA on dental AI regulation. The segment also contains a mid-roll advertisement read by Nathan. | |
| Raising $26M in Venture Capital and Series A Dynamics | 6 | 2 | 2 | 5 | Nathan walks through Vidya's capitalization history and estimates their Series A valuation at over $150M based on standard dilution benchmarks. When Florian hints at having predicted the VC downturn early, Nathan jokingly calls him out for hindsight bias. | |
| Team Expansion and Monthly Recurring Revenue Estimation | 6 | 5 | 3 | 6 | Nathan calculates Florian's minimum MRR floor using previously stated unit economics when Florian hedges on disclosing exact revenue. Florian also educates Nathan on the FDA's 'Software as a Medical Device' classification and how they monetized insurance adjudication prior to clinical approval. | |
| Post-Series A Growth Expectations with Spark Capital | 4 | 1 | 1 | 4 | Nathan outlines the high ARR growth expectations associated with taking a $20M Series A from top-tier VCs like Spark Capital. The interview concludes smoothly with Nathan's standard 'Famous Five' rapid-fire questions. |